Status:
UNKNOWN
Impact of V106I on Resistance to Doravirine
Lead Sponsor:
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Conditions:
HIV-1-infection
Eligibility:
All Genders
13-75 years
Brief Summary
Objective. To study the impact of V106I mutation in the reverse transcriptase of HIV-1 on the activity of Doravirine. Clinical hypotheses. Doravirine shows a unique resistance pattern with a higher ...
Detailed Description
Testing for transmitted drug resistance (TDR) in the reverse transcriptase and protease in newly diagnosed patients with HIV is recommended by treatment guidelines. Currently clinical practice for fir...
Eligibility Criteria
Inclusion
- Antiretroviral-naïve subjects over 13 years of age, including both seroprevalent and seroconverter patients
Exclusion
- Patients with prior antiretroviral exposure
- \-
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04894357
Start Date
September 1 2021
End Date
May 1 2022
Last Update
August 18 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.